Alzheimer’s Disease

Last Updated: October 17, 2023

Alzheimer’s disease is a neurodegenerative disorder that impairs cognitive function, especially memory formation. It is the most common type of dementia.

Alzheimer’s Disease falls under theBrain HealthandHealthy Aging & Longevitycategories.

What is Alzheimer’s disease?

Alzheimer’s disease is a form of dementia, a general term for neurological conditions that impair cognitive function to the point of interfering with daily life. It is the most common type of dementia (representing around 60 to 80% of cases) and involves a progressive degeneration of brain cells. Alzheimer’s disease is currently the fifth-leading cause of death for people older than 65 in the United States.[1]

What are the main signs and symptoms of Alzheimer’s disease?

One of the first symptoms of Alzheimer’s disease is memory loss, especially short-term memory loss of events and experiences.[8] Other common symptoms of early disease include worsening verbal memory, impaired problem solving, lack of motivation, depression, and sleep disorders. In later stages of disease, memory and cognition continue to worsen, causing disability and deterioration of motor function, in addition to significant personality changes, behavioral changes, and psychosis.

How is Alzheimer’s disease diagnosed?

A conclusive diagnosis of Alzheimer’s disease requires examining the brain during autopsy, meaning it can’t be definitively diagnosed in someone while they are alive. Still, doctors can make a possible or probable diagnosis based on signs and symptoms, performance on neurocognitive tests (which assess things like memory, concentration, and reasoning), and the exclusion of other causes. More recently developed diagnostic methods using ​​positron-emission tomography (PET) scans can identify amyloid accumulation (an indicator of Alzheimer’s disease) with a high level of accuracy, but this testing remains limited and is used primarily for research purposes at this time.[9]

What are some of the main medical treatments for Alzheimer’s disease?

No medical treatments have been clearly shown to stop or slow the underlying disease process in Alzheimer’s disease. However, some medication can improve symptoms. Acetylcholinesterase inhibitors can improve cognitive function in people with Alzheimer’s disease, although the effect is generally small.[14]

In 2020, a medication called aducanumab was approved by the FDA for the treatment of Alzheimer’s disease based on its effects on amyloid plaques, but whether aducanumab improves clinical outcomes (e.g., cognitive function) remains to be established.[15]

How could diet affect Alzheimer’s disease?

A few dietary patterns are associated with a lower risk of Alzheimer’s disease. This protective relationship is perhaps most commonly found with a Mediterranean diet. Among individual components of the diet, a higher intake of saturated fat and sugar has been linked to a higher risk of Alzheimer’s disease, while a higher intake of fish has been linked to a lower risk. Unfortunately, these findings derive from observational studies, meaning cause and effect can’t be determined with certainty, and there are almost no randomized clinical trials (RCTs) looking at the effect of diet on the incidence of Alzheimer’s disease.

Have any supplements been studied for Alzheimer’s disease?

RCTs have assessed a number of supplements’ effects on established Alzheimer’s disease. This includes omega-3s, B vitamins (usually folic acid, vitamin B6, and vitamin B12), vitamin D, vitamin E, ginkgo biloba, L-alpha glycerylphosphorylcholine (alpha-GPC), Lion's mane mushroom, ginseng, saffron, and sodium oligomannate. For the most part, these supplements have only conflicting or limited evidence in favor of their use.

Are there any other treatments for Alzheimer’s disease?

Exercise and physical activity have been shown to benefit physical function, functional independence, and neuropsychiatric symptoms in people with Alzheimer’s disease; aerobic exercise specifically improved cognitive function.

Several trials have investigated the effect of a keto diet and ketogenic supplements (e.g., medium-chain triglycerides) on Alzheimer’s disease and observed improvements — sometimes, but not always — in quality of life and cognitive function.

Music therapy centers around listening to music to stimulate the brain. Some research suggests the intervention can improve mood and cognitive function among people who have Alzheimer’s disease.

What causes Alzheimer’s disease?

The underlying cause of Alzheimer’s is not known for certain, but several explanations have been proposed. The most common theory is that Alzheimer’s disease is the result of neurodegeneration and a buildup of misfolded proteins called amyloid plaques and tau tangles, which are almost always found in the brains of people with the disease. However, this “amyloid hypothesis” has been criticized. Regardless of the cause of Alzheimer’s disease, various modifiable and nonmodifiable factors, including aging, depression, diabetes, and genetics, have been linked to a higher risk of the disease.

Supplements Demystified: Get Our Unbiased, Evidence-Based Guide

Looking for a Supplement guide?

Our Supplement Guides give you unbiased research-based recommendations that you can immediately apply to improve your health. Alzheimer’s Disease is related to the following Supplement Guides:
Examine Database: Alzheimer’s Disease
What works and what doesn't?

Unlock the full potential of Examine

Get started

Don't miss out on the latest research

Update History
2023-10-17 00:30:02

Citations added


A statement in the FAQs about the effect of music therapy on cognitive function was missing references, so we added them.

Reviewed By

2023-10-16 00:30:03

Expert review complete


This page underwent expert review by on of our physician reviewers.

Reviewed By

  1. ^2021 Alzheimer's disease facts and figures.Alzheimers Dement.(2021 Mar)
  2. ^Jahn HMemory loss in Alzheimer's disease.Dialogues Clin Neurosci.(2013-Dec)
  3. ^Mortamais M, Ash JA, Harrison J, Kaye J, Kramer J, Randolph C, Pose C, Albala B, Ropacki M, Ritchie CW, Ritchie KDetecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility.Alzheimers Dement.(2017-Apr)
  4. ^Mitchell AJ, Shiri-Feshki MRate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies.Acta Psychiatr Scand.(2009-Apr)
  5. ^Carrie D. Patnode, Leslie A. Perdue, Rebecca C. Rossom, Megan C. Rushkin, Nadia Redmond, Rachel G. Thomas, Jennifer S. LinScreening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force Internet
  6. ^Han L, Cole M, Bellavance F, McCusker J, Primeau FTracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis.Int Psychogeriatr.(2000-Jun)
  7. ^Clark CM, Sheppard L, Fillenbaum GG, Galasko D, Morris JC, Koss E, Mohs R, Heyman AVariability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease.Arch Neurol.(1999-Jul)
  8. ^Kumar A, Sidhu J, Goyal A, Tsao JWAlzheimer DiseaseStatPearls.(2022-06)
  9. ^Weller J, Budson ACurrent understanding of Alzheimer's disease diagnosis and treatment.F1000Res.(2018)
  10. ^Silvia Duong, Tejal Patel, Feng ChangDementia: What pharmacists need to knowCan Pharm J (Ott).(2017 Feb 7)
  11. ^David B Hogan, Nathalie Jetté, Kirsten M Fiest, Jodie I Roberts, Dawn Pearson, Eric E Smith, Pamela Roach, Andrew Kirk, Tamara Pringsheim, Colleen J MaxwellThe Prevalence and Incidence of Frontotemporal Dementia: a Systematic ReviewCan J Neurol Sci.(2016 Apr)
  12. ^Tripathi M, Vibha DReversible dementias.Indian J Psychiatry.(2009-Jan)
  13. ^Schilling LP, Zimmer ER, Shin M, Leuzy A, Pascoal TA, Benedet AL, Borelli WV, Palmini A, Gauthier S, Rosa-Neto PImaging Alzheimer's disease pathophysiology with PET.Dement Neuropsychol.(2016)
  14. ^Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta FEfficacy of acetylcholinesterase inhibitors in Alzheimer's disease.Neuropharmacology.(2021-06-01)
  15. ^Tampi RR, Forester BP, Agronin MAducanumab: evidence from clinical trial data and controversies.Drugs Context.(2021)
  16. ^Longjian Liu, Stella L Volpe, Jennifer A Ross, Jessica A Grimm, Elisabeth J Van Bockstaele, Howard J EisenDietary sugar intake and risk of Alzheimer's disease in older womenNutr Neurosci.(2021 Jul 30)
  17. ^Mio Ozawa, Tomoyuki Ohara, Toshiharu Ninomiya, Jun Hata, Daigo Yoshida, Naoko Mukai, Masaharu Nagata, Kazuhiro Uchida, Tomoko Shirota, Takanari Kitazono, Yutaka KiyoharaMilk and dairy consumption and risk of dementia in an elderly Japanese population: the Hisayama StudyJ Am Geriatr Soc.(2014 Jul)
  18. ^Jounghee Lee, Zhuxuan Fu, Mei Chung, Dai-Ja Jang, Hae-Jeung LeeRole of milk and dairy intake in cognitive function in older adults: a systematic review and meta-analysisNutr J.(2018 Aug 27)
  19. ^Claire T McEvoy, Yue Leng, Geeske Mee Peeters, Allison R Kaup, Isabel E Allen, Kristine YaffeInterventions involving a major dietary component improve cognitive function in cognitively healthy adults: a systematic review and meta-analysisNutr Res.(2019 Jun)
  20. ^Klodian Dhana, Denis A Evans, Kumar B Rajan, David A Bennett, Martha C MorrisHealthy lifestyle and the risk of Alzheimer dementia: Findings from 2 longitudinal studiesNeurology.(2020 Jul 28)
  21. ^M Paul Murphy, Harry LeVine 3rdAlzheimer's disease and the amyloid-beta peptideJ Alzheimers Dis.(2010)
  22. ^Michael A Castello, Salvador SorianoOn the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesisAgeing Res Rev.(2014 Jan)
  23. ^Li-Kai Huang, Shu-Ping Chao, Chaur-Jong HuClinical trials of new drugs for Alzheimer diseaseJ Biomed Sci.(2020 Jan 6)
  24. ^Athanasios Metaxas, Stefan J KempfNeurofibrillary tangles in Alzheimer's disease: elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomicsNeural Regen Res.(2016 Oct)
  25. ^Lisa Mosconi, Alberto Pupi, Mony J De LeonBrain glucose hypometabolism and oxidative stress in preclinical Alzheimer's diseaseAnn N Y Acad Sci.(2008 Dec)
  26. ^Suzanne M de la Monte, Jack R WandsAlzheimer's disease is type 3 diabetes-evidence reviewedJ Diabetes Sci Technol.(2008 Nov)
  27. ^Yuri Zilberter, Misha ZilberterThe vicious circle of hypometabolism in neurodegenerative diseases: Ways and mechanisms of metabolic correctionJ Neurosci Res.(2017 Nov)
  28. ^Takako Niikura, Hirohisa Tajima, Yoshiko KitaNeuronal cell death in Alzheimer's disease and a neuroprotective factor, humaninCurr Neuropharmacol.(2006 Apr)
  29. ^2020 Alzheimer's disease facts and figures.Alzheimers Dement.(2020 Mar 10)
  30. ^Sáiz-Vázquez O, Gracia-García P, Ubillos-Landa S, Puente-Martínez A, Casado-Yusta S, Olaya B, Santabárbara JDepression as a Risk Factor for Alzheimer's Disease: A Systematic Review of Longitudinal Meta-Analyses.J Clin Med.(2021-Apr-21)
  31. ^Harerimana NV, Liu Y, Gerasimov ES, Duong D, Beach TG, Reiman EM, Schneider JA, Boyle P, Lori A, Bennett DA, Lah JJ, Levey AI, Seyfried NT, Wingo TS, Wingo APGenetic Evidence Supporting a Causal Role of Depression in Alzheimer's Disease.Biol Psychiatry.(2022-07-01)
  32. ^S Seshadri, P A Wolf, A Beiser, R Au, K McNulty, R White, R B D'AgostinoLifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham StudyNeurology.(1997 Dec)
  33. ^Beam CR, Kaneshiro C, Jang JY, Reynolds CA, Pedersen NL, Gatz MDifferences Between Women and Men in Incidence Rates of Dementia and Alzheimer's Disease.J Alzheimers Dis.(2018)
  34. ^Salk RH, Hyde JS, Abramson LYGender differences in depression in representative national samples: Meta-analyses of diagnoses and symptoms.Psychol Bull.(2017-Aug)
  35. ^Song YJ, Li SR, Li XW, Chen X, Wei ZX, Liu QS, Cheng YThe Effect of Estrogen Replacement Therapy on Alzheimer's Disease and Parkinson's Disease in Postmenopausal Women: A Meta-Analysis.Front Neurosci.(2020)
  36. ^Snowden TM, Hinde AK, Reid HMO, Christie BRDoes Mild Traumatic Brain Injury Increase the Risk for Dementia? A Systematic Review and Meta-Analysis.J Alzheimers Dis.(2020)
  37. ^Gu D, Ou S, Liu GTraumatic Brain Injury and Risk of Dementia and Alzheimer's Disease: A Systematic Review and Meta-Analysis.Neuroepidemiology.(2022)
  38. ^Li Y, Li Y, Li X, Zhang S, Zhao J, Zhu X, Tian GHead Injury as a Risk Factor for Dementia and Alzheimer's Disease: A Systematic Review and Meta-Analysis of 32 Observational Studies.PLoS One.(2017)
  39. ^Stern YWhat is cognitive reserve? Theory and research application of the reserve concept.J Int Neuropsychol Soc.(2002-Mar)
  40. ^Stern YCognitive reserve.Neuropsychologia.(2009-Aug)
  41. ^Jin-Tai Yu, Wei Xu, Chen-Chen Tan, Sandrine Andrieu, John Suckling, Evangelos Evangelou, An Pan, Can Zhang, Jianping Jia, Lei Feng, Ee-Heok Kua, Yan-Jiang Wang, Hui-Fu Wang, Meng-Shan Tan, Jie-Qiong Li, Xiao-He Hou, Yu Wan, Lin Tan, Vincent Mok, Lan Tan, Qiang Dong, Jacques Touchon, Serge Gauthier, Paul S Aisen, Bruno VellasEvidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trialsJ Neurol Neurosurg Psychiatry.(2020 Jul 20)
  42. ^Bowren M, Tranel D, Boes ADPreserved Cognition After Right Hemispherectomy.Neurol Clin Pract.(2021-Dec)
  43. ^Mandolesi L, Gelfo F, Serra L, Montuori S, Polverino A, Curcio G, Sorrentino GEnvironmental Factors Promoting Neural Plasticity: Insights from Animal and Human Studies.Neural Plast.(2017)
  44. ^Guure CB, Ibrahim NA, Adam MB, Said SMImpact of Physical Activity on Cognitive Decline, Dementia, and Its Subtypes: Meta-Analysis of Prospective Studies.Biomed Res Int.(2017)
  45. ^Gudala K, Bansal D, Schifano F, Bhansali ADiabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies.J Diabetes Investig.(2013-Nov-27)
  46. ^Vagelatos NT, Eslick GDType 2 diabetes as a risk factor for Alzheimer's disease: the confounders, interactions, and neuropathology associated with this relationship.Epidemiol Rev.(2013)
  47. ^Li X, Song D, Leng SXLink between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment.Clin Interv Aging.(2015)
  48. ^Kuo CL, Lu CL, Chang YH, Li CYPopulation-Based Cohort Study on Dementia Risk in Patients with Type 1 Diabetes Mellitus.Neuroepidemiology.(2018)
  49. ^Gilsanz P, Schnaider Beeri M, Karter AJ, Quesenberry CP, Adams AS, Whitmer RADepression in type 1 diabetes and risk of dementia.Aging Ment Health.(2019-07)
  50. ^Yi Qu, He-Ying Hu, Ya-Nan Ou, Xue-Ning Shen, Wei Xu, Zuo-Teng Wang, Qiang Dong, Lan Tan, Jin-Tai YuAssociation of body mass index with risk of cognitive impairment and dementia: A systematic review and meta-analysis of prospective studiesNeurosci Biobehav Rev.(2020 Aug)
  51. ^Singh-Manoux A, Dugravot A, Shipley M, Brunner EJ, Elbaz A, Sabia S, Kivimaki MObesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II Study.Alzheimers Dement.(2018-02)
  52. ^Ou YN, Tan CC, Shen XN, Xu W, Hou XH, Dong Q, Tan L, Yu JTBlood Pressure and Risks of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of 209 Prospective Studies.Hypertension.(2020-07)
  53. ^Tan X, Sundström J, Lind L, Franzon K, Kilander L, Benedict CReverse Dipping of Systolic Blood Pressure Is Associated With Increased Dementia Risk in Older Men: A Longitudinal Study Over 24 Years.Hypertension.(2021-04)
  54. ^de Heus RAA, Tzourio C, Lee EJL, Opozda M, Vincent AD, Anstey KJ, Hofman A, Kario K, Lattanzi S, Launer LJ, Ma Y, Mahajan R, Mooijaart SP, Nagai M, Peters R, Turnbull D, Yano Y, , Claassen JAHR, Tully PJAssociation Between Blood Pressure Variability With Dementia and Cognitive Impairment: A Systematic Review and Meta-Analysis.Hypertension.(2021-11)
  55. ^Gosztyla ML, Brothers HM, Robinson SRAlzheimer's Amyloid-β is an Antimicrobial Peptide: A Review of the Evidence.J Alzheimers Dis.(2018)
  56. ^Steel AJ, Eslick GDHerpes Viruses Increase the Risk of Alzheimer's Disease: A Meta-Analysis.J Alzheimers Dis.(2015)
  57. ^Eimer WA, Vijaya Kumar DK, Navalpur Shanmugam NK, Rodriguez AS, Mitchell T, Washicosky KJ, György B, Breakefield XO, Tanzi RE, Moir RDAlzheimer's Disease-Associated β-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection.Neuron.(2018-07-11)
  58. ^Kamer AR, Craig RG, Niederman R, Fortea J, de Leon MJPeriodontal disease as a possible cause for Alzheimer's disease.Periodontol 2000.(2020-06)
  59. ^Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, Nguyen M, Haditsch U, Raha D, Griffin C, Holsinger LJ, Arastu-Kapur S, Kaba S, Lee A, Ryder MI, Potempa B, Mydel P, Hellvard A, Adamowicz K, Hasturk H, Walker GD, Reynolds EC, Faull RLM, Curtis MA, Dragunow M, Potempa Jin Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors.Sci Adv.(2019-01)
  60. ^Jeffrey J Iliff, Minghuan Wang, Yonghong Liao, Benjamin A Plogg, Weiguo Peng, Georg A Gundersen, Helene Benveniste, G Edward Vates, Rashid Deane, Steven A Goldman, Erlend A Nagelhus, Maiken NedergaardA paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid βSci Transl Med.(2012 Aug 15)
  61. ^Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, O'Donnell J, Christensen DJ, Nicholson C, Iliff JJ, Takano T, Deane R, Nedergaard MSleep drives metabolite clearance from the adult brainScience.(2013 Oct 18)
  62. ^Fan L, Xu W, Cai Y, Hu Y, Wu CSleep Duration and the Risk of Dementia: A Systematic Review and Meta-analysis of Prospective Cohort Studies.J Am Med Dir Assoc.(2019-12)
  63. ^Kurina LM, McClintock MK, Chen JH, Waite LJ, Thisted RA, Lauderdale DSSleep duration and all-cause mortality: a critical review of measurement and associations.Ann Epidemiol.(2013-Jun)
  64. ^Wang C, Holtzman DMBidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors.Neuropsychopharmacology.(2020-01)
  65. ^Omonigho M Bubu, Michael Brannick, James Mortimer, Ogie Umasabor-Bubu, Yuri V Sebastião, Yi Wen, Skai Schwartz, Amy R Borenstein, Yougui Wu, David Morgan, William M AndersonSleep, Cognitive impairment, and Alzheimer's disease: A Systematic Review and Meta-AnalysisSleep.(2017 Jan 1)
  66. ^Natalia García-Casares, Paloma Gallego Fuentes, Miguel Ángel Barbancho, Rosa López-Gigosos, Antonio García-Rodríguez, Mario Gutiérrez-BedmarAlzheimer's Disease, Mild Cognitive Impairment and Mediterranean Diet. A Systematic Review and Dose-Response Meta-AnalysisJ Clin Med.(2021 Oct 10)
  67. ^Martha Clare Morris, Christy C Tangney, Yamin Wang, Frank M Sacks, David A Bennett, Neelum T AggarwalMIND diet associated with reduced incidence of Alzheimer's diseaseAlzheimers Dement.(2015 Sep)
  68. ^Miao H, Chen K, Yan X, Chen FSugar in Beverage and the Risk of Incident Dementia, Alzheimer's Disease and Stroke: A Prospective Cohort Study.J Prev Alzheimers Dis.(2021)
  69. ^Shunquan Wu, Yingying Ding, Fuquan Wu, Ruisheng Li, Jun Hou, Panyong MaoOmega-3 fatty acids intake and risks of dementia and Alzheimer's disease: a meta-analysisNeurosci Biobehav Rev.(2015 Jan)
  70. ^Samieri C, Morris MC, Bennett DA, Berr C, Amouyel P, Dartigues JF, Tzourio C, Chasman DI, Grodstein FFish Intake, Genetic Predisposition to Alzheimer Disease, and Decline in Global Cognition and Memory in 5 Cohorts of Older Persons.Am J Epidemiol.(2018-05-01)
  71. ^Susanna C Larsson, Nicola OrsiniCoffee Consumption and Risk of Dementia and Alzheimer's Disease: A Dose-Response Meta-Analysis of Prospective StudiesNutrients.(2018 Oct 14)
  72. ^Yuan Zhang, Hongxi Yang, Shu Li, Zhi Cao, Wei-Dong Li, Tao Yan, Yaogang WangAssociation of coffee and genetic risk with incident dementia in middle-aged and elderly adultsNutr Neurosci.(2021 Aug 23)
  73. ^Anstey KJ, Mack HA, Cherbuin NAlcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies.Am J Geriatr Psychiatry.(2009-Jul)
  74. ^Xu W, Tan L, Wang HF, Jiang T, Tan MS, Tan L, Zhao QF, Li JQ, Wang J, Yu JTMeta-analysis of modifiable risk factors for Alzheimer's disease.J Neurol Neurosurg Psychiatry.(2015-Dec)
  75. ^Costanzo S, de Gaetano G, Di Castelnuovo A, Djoussé L, Poli A, van Velden DPModerate alcohol consumption and lower total mortality risk: Justified doubts or established facts?Nutr Metab Cardiovasc Dis.(2019-10)
  76. ^Andrews SJ, Goate A, Anstey KJAssociation between alcohol consumption and Alzheimer's disease: A Mendelian randomization study.Alzheimers Dement.(2020-02)
  77. ^Kivimäki M, Singh-Manoux A, Batty GD, Sabia S, Sommerlad A, Floud S, Jokela M, Vahtera J, Beydoun MA, Suominen SB, Koskinen A, Väänänen A, Goldberg M, Zins M, Alfredsson L, Westerholm PJM, Knutsson A, Nyberg ST, Sipilä PN, Lindbohm JV, Pentti J, Livingston G, Ferrie JE, Strandberg TAssociation of Alcohol-Induced Loss of Consciousness and Overall Alcohol Consumption With Risk for Dementia.JAMA Netw Open.(2020-09-01)
  78. ^Zuin M, Cervellati C, Brombo G, Trentini A, Roncon L, Zuliani GElevated Blood Homocysteine and Risk of Alzheimer's Dementia: An Updated Systematic Review and Meta-Analysis Based on Prospective Studies.J Prev Alzheimers Dis.(2021)
  79. ^Jevtic S, Sengar AS, Salter MW, McLaurin JThe role of the immune system in Alzheimer disease: Etiology and treatment.Ageing Res Rev.(2017-Nov)
  80. ^Wang L, Qiao Y, Zhang H, Zhang Y, Hua J, Jin S, Liu GCirculating Vitamin D Levels and Alzheimer's Disease: A Mendelian Randomization Study in the IGAP and UK Biobank.J Alzheimers Dis.(2020)
  81. ^Larsson SC, Traylor M, Markus HS, Michaëlsson KSerum Parathyroid Hormone, 25-Hydroxyvitamin D, and Risk of Alzheimer's Disease: A Mendelian Randomization Study.Nutrients.(2018-Sep-06)
  82. ^Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MAOxidative damage is the earliest event in Alzheimer disease.J Neuropathol Exp Neurol.(2001-Aug)
  83. ^Gella A, Durany NOxidative stress in Alzheimer disease.Cell Adh Migr.(2009)
  84. ^Dyall SCLong-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA.Front Aging Neurosci.(2015)
  85. ^Yan L, Xie Y, Satyanarayanan SK, Zeng H, Liu Q, Huang M, Ma Y, Wan JB, Yao X, Su KP, Su HOmega-3 polyunsaturated fatty acids promote brain-to-blood clearance of β-Amyloid in a mouse model with Alzheimer's disease.Brain Behav Immun.(2020-03)
  86. ^Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem N, Frautschy SA, Cole GMA diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model.J Neurosci.(2005-Mar-23)
  87. ^Ibach B, Haen EAcetylcholinesterase inhibition in Alzheimer's Disease.Curr Pharm Des.(2004)
  88. ^Ameneh Mashayekh, Dzung L Pham, David M Yousem, Mercedes Dizon, Peter B Barker, Doris D M LinEffects of Ginkgo biloba on cerebral blood flow assessed by quantitative MR perfusion imaging: a pilot studyNeuroradiology.(2011 Mar)
  89. ^Shi C, Liu J, Wu F, Yew DTGinkgo biloba extract in Alzheimer's disease: from action mechanisms to medical practice.Int J Mol Sci.(2010-Jan-08)
  90. ^Kim HJ, Shin EJ, Lee BH, Choi SH, Jung SW, Cho IH, Hwang SH, Kim JY, Han JS, Chung C, Jang CG, Rhim H, Kim HC, Nah SYOral Administration of Gintonin Attenuates Cholinergic Impairments by Scopolamine, Amyloid-β Protein, and Mouse Model of Alzheimer's Disease.Mol Cells.(2015-Sep)
  91. ^Kim HJ, Kim DJ, Shin EJ, Lee BH, Choi SH, Hwang SH, Rhim H, Cho IH, Kim HC, Nah SYEffects of gintonin-enriched fraction on hippocampal cell proliferation in wild-type mice and an APPswe/PSEN-1 double Tg mouse model of Alzheimer's disease.Neurochem Int.(2016-12)
  92. ^Zhang J, Wang Y, Dong X, Liu JCrocetin attenuates inflammation and amyloid-β accumulation in APPsw transgenic mice.Immun Ageing.(2018)
  93. ^Asadi F, Jamshidi AH, Khodagholi F, Yans A, Azimi L, Faizi M, Vali L, Abdollahi M, Ghahremani MH, Sharifzadeh MReversal effects of crocin on amyloid β-induced memory deficit: Modification of autophagy or apoptosis markers.Pharmacol Biochem Behav.(2015-Dec)
  94. ^Batarseh YS, Bharate SS, Kumar V, Kumar A, Vishwakarma RA, Bharate SB, Kaddoumi ACrocus sativus Extract Tightens the Blood-Brain Barrier, Reduces Amyloid β Load and Related Toxicity in 5XFAD Mice.ACS Chem Neurosci.(2017-08-16)
  95. ^Hadipour M, Kaka G, Bahrami F, Meftahi GH, Pirzad Jahromi G, Mohammadi A, Sahraei HCrocin improved amyloid beta induced long-term potentiation and memory deficits in the hippocampal CA1 neurons in freely moving rats.Synapse.(2018-05)
  96. ^Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T, Xie Z, Chu X, Yang J, Wang H, Chang S, Gong Y, Ruan L, Zhang G, Yan S, Lian W, Du C, Yang D, Zhang Q, Lin F, Liu J, Zhang H, Ge C, Xiao S, Ding J, Geng MSodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression.Cell Res.(2019-Oct)
  97. ^Christian-Alexandre Castellano, Scott Nugent, Nancy Paquet, Sébastien Tremblay, Christian Bocti, Guy Lacombe, Hélène Imbeault, Éric Turcotte, Tamas Fulop, Stephen C CunnaneLower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer's disease dementiaJ Alzheimers Dis.(2015)
  98. ^Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LCStudy of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trialNutr Metab (Lond).(2009 Aug 10)
  99. ^Matthew C L Phillips, Laura M Deprez, Grace M N Mortimer, Deborah K J Murtagh, Stacey McCoy, Ruth Mylchreest, Linda J Gilbertson, Karen M Clark, Patricia V Simpson, Eileen J McManus, Jee-Eun Oh, Satish Yadavaraj, Vanessa M King, Avinesh Pillai, Beatriz Romero-Ferrando, Martijn Brinkhuis, Bronwyn M Copeland, Shah Samad, Shenyang Liao, Jan A C SchepelRandomized crossover trial of a modified ketogenic diet in Alzheimer's diseaseAlzheimers Res Ther.(2021 Feb 23)
Examine Database References
  1. Alzheimer's Disease Symptoms - Jingya Jia, Jing Hu, Xiaoxu Huo, Rujuan Miao, Yanping Zhang, Fei MaEffects of vitamin D supplementation on cognitive function and blood Aβ-related biomarkers in older adults with Alzheimer's disease: a randomised, double-blind, placebo-controlled trialJ Neurol Neurosurg Psychiatry.(2019 Dec)
  2. Alzheimer's Disease Symptoms - I-Chen Li, Han-Hsin Chang, Chuan-Han Lin, Wan-Ping Chen, Tsung-Han Lu, Li-Ya Lee, Yu-Wen Chen, Yen-Po Chen, Chin-Chu Chen, David Pei-Cheng LinPrevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled StudyFront Aging Neurosci.(2020 Jun 3)
  3. Alzheimer's Disease Symptoms - Soon-Tae Lee, Kon Chu, Ji-Young Sim, Jae-Hyeok Heo, Manho KimPanax ginseng enhances cognitive performance in Alzheimer diseaseAlzheimer Dis Assoc Disord.(Jul-Sep 2008)
  4. Alzheimer's Disease Symptoms - Jae-Hyeok Heo, Soon-Tae Lee, Min Jung Oh, Hyun-Jung Park, Ji-Young Shim, Kon Chu, Manho KimImprovement of cognitive deficit in Alzheimer's disease patients by long term treatment with korean red ginsengJ Ginseng Res.(2011 Nov)
  5. Alzheimer's Disease Symptoms - Jae-Hyeok Heo, Soon-Tae Lee, Kon Chu, Min Jung Oh, Hyun-Jung Park, Ji-Young Shim, Manho KimHeat-processed ginseng enhances the cognitive function in patients with moderately severe Alzheimer's diseaseNutr Neurosci.(2012 Nov)
  6. Alzheimer's Disease Symptoms - Lee, Soon-Tae., Chu, Kon., Kim, Jeong-Min., Park, Hyun-Jeong., Kim, Man-Ho Cognitive improvement by ginseng in Alzheimer's diseaseJournal of Ginseng Research.()
  7. Cognitive Decline - Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, Shim JY, Kim MAn open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's diseaseEur J Neurol.(2008 Aug)
  8. Alzheimer's Disease Symptoms - Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PDEffect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trialJAMA.(2014 Jan 1)
  9. Alzheimer's Disease Symptoms - Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJA controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative StudyN Engl J Med.(1997 Apr 24)
  10. Alzheimer's Disease Risk - Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ, Alzheimer's Disease Cooperative Study GroupVitamin E and donepezil for the treatment of mild cognitive impairmentN Engl J Med.(2005 Jun 9)
  11. Alzheimer's Disease Symptoms - Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PSDocosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trialJAMA.(2010 Nov 3)
  12. Alzheimer's Disease Symptoms - Green RC, Goldstein FC, Auchus AP, Presley R, Clark WS, Van Tuyl L, Green J, Hersch SM, Karp HRTreatment trial of oxiracetam in Alzheimer's diseaseArch Neurol.(1992 Nov)
  13. Alzheimer's Disease Symptoms - Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SSh, Yousefi MH, Alimardani R, Jamshidi A, Zare F, Moradi ASaffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trialJ Clin Pharm Ther.(2010 Oct)
  14. Alzheimer's Disease Symptoms - Mehdi Farokhnia, Mehdi Shafiee Sabet, Negar Iranpour, Amirhossein Gougol, Habibeh Yekehtaz, Roozbeh Alimardani, Farzaneh Farsad, Maryam Kamalipour, Shahin AkhondzadehComparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trialHum Psychopharmacol.(2014 Jul)
  15. Alzheimer's Disease Symptoms - Akhondzadeh S, Shafiee Sabet M, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SS, Yousefi MH, Alimardani R, Jamshidi A, Rezazadeh SA, Yousefi A, Zare F, Moradi A, Vossoughi AA 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's diseasePsychopharmacology (Berl).(2010 Jan)
  16. Alzheimer's Disease Symptoms - Sudesh Prabhakar, Venugopalan Y Vishnu, Manish Modi, Manju Mohanty, Anchal Sharma, Bikas Medhi, B R Mittal, Niranjan Khandelwal, Manoj K Goyal, Vivek Lal, Rajesh Singla, Avinash Kansal, Ajit AvasthiEfficacy of Bacopa Monnieri (Brahmi) and Donepezil in Alzheimer's Disease and Mild Cognitive Impairment: A Randomized Double-Blind Parallel Phase 2b StudyAnn Indian Acad Neurol.(Nov-Dec 2020)
  17. Alzheimer's Disease Symptoms - Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefke SGinkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mgJ Psychiatr Res.(2012 Jun)
  18. Alzheimer's Disease Symptoms - Ihl R, Tribanek M, Bachinskaya N, GOTADAY Study GroupEfficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trialPharmacopsychiatry.(2012 Mar)
  19. Cognitive Decline - Yancheva S, Ihl R, Nikolova G, Panayotov P, Schlaefke S, Hoerr R, GINDON Study GroupGinkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trialAging Ment Health.(2009 Mar)
  20. Cognitive Decline - Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S, GuidAge Study GroupLong-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trialLancet Neurol.(2012 Oct)
  21. Alzheimer's Disease Symptoms - Barak Y, Levine J, Glasman A, Elizur A, Belmaker RHInositol treatment of Alzheimer's disease: a double blind, cross-over placebo controlled trialProg Neuropsychopharmacol Biol Psychiatry.(1996 May)
  22. Alzheimer's Disease Symptoms - Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM, ELND005-AD201 InvestigatorsA phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer diseaseNeurology.(2011 Sep 27)
  23. Alzheimer's Disease Symptoms - De Jesus Moreno Moreno MCognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trialClin Ther.(2003 Jan)
  24. Cognitive Decline - Engel RR, Satzger W, Günther W, Kathmann N, Bove D, Gerke S, Münch U, Hippius HDouble-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer typeEur Neuropsychopharmacol.(1992 Jun)
  25. Cognitive Decline - Crook T, Petrie W, Wells C, Massari DCEffects of phosphatidylserine in Alzheimer's diseasePsychopharmacol Bull.(1992)
  26. Cognitive Decline - Klinkhammer P, Szelies B, Heiss W.D.Effect of Phosphatidylserine on Cerebral Glucose Metabolism in Alzheimer's DiseaseDementia and Geriatric Cognitive Disorders.()
  27. Cognitive Decline - Dubois B, Zaim M, Touchon J, Vellas B, Robert P, Murphy MF, Pujadas-Navinés F, Rainer M, Soininen H, Riordan HJ, Kanony-Truc CEffect of six months of treatment with V0191 in patients with suspected prodromal Alzheimer's diseaseJ Alzheimers Dis.(2012)
  28. Cognitive Decline - Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok VSix-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer diseaseJ Clin Psychopharmacol.(2008 Feb)
  29. Cognitive Decline - Croisile B, Trillet M, Fondarai J, Laurent B, Mauguière F, Billardon MLong-term and high-dose piracetam treatment of Alzheimer's diseaseNeurology.(1993 Feb)
  30. Cognition - Chiu S, Gericke N, Farina-Woodbury M, Badmaev V, Raheb H, Terpstra K, Antongiorgi J, Bureau Y, Cernovsky Z, Hou J, Sanchez V, Williams M, Copen J, Husni M, Goble LProof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Sceletium tortuosum (Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects: Implications for Alzheimer's DementiaEvid Based Complement Alternat Med.(2014)
  31. Dementia Symptoms - Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DLDown syndrome and dementia: a randomized, controlled trial of antioxidant supplementationAm J Med Genet A.(2011 Aug)
  32. C-Reactive Protein (CRP) - Armita Mahdavi Gorabi, Saeed Aslani, Danyal Imani, Bahman Razi, Thozhukat Sathyapalan, Amirhossein SahebkarEffect of resveratrol on C-reactive protein: An updated meta-analysis of randomized controlled trialsPhytother Res.(2021 Dec)
  33. Weight - Mousavi SM, Milajerdi A, Sheikhi A, Kord-Varkaneh H, Feinle-Bisset C, Larijani B, Esmaillzadeh AResveratrol supplementation significantly influences obesity measures: a systematic review and dose-response meta-analysis of randomized controlled trials.Obes Rev.(2019-Mar)